Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia

a pilot study

Blanco, José L
Rojas, Jhon
de Lazzari, Elisa
Inciarte, Alexy
Subirana, Mar
Callau, Pilar
Martinez-Rebollar, María
Laguno, Montserrat
Mallolas, Josep
de la Mora, Lorena
Torres, Berta
Gonzalez-Cordón, Ana
Martinez, Esteban

Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
Infectious Diseases Department Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain

Corresponding author. E-mail: [email protected], [email protected]

Received November 11, 2021

Accepted February 18, 2022

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Journal of Antimicrobial Chemotherapy 77(7):p 1974-1979, July 2022. | DOI: 10.1093/jac/dkac137